| [Objective]Condyloma acuminate and Chlamydia trachomatis infection are the common sexually transmitted disease,but there is paucity of data on the co-i nfection.High risk human papillomavirus(HR-HPV)associated with Chlamydia trachomatis is considered as the main etiologyl for cervical neoplasia.The ai m of this study was to investigate the prevalence of Chlamydia trachomatis an d cervical Human papillomavirus(HPV)genotypes,especially their co-infection among females who presented to the sexually transmitted diseases(STD)depar tment of Tianjin Medicine University affiliated general hospital with external g enital warts(EGWs),and the effect of Recombinant Human Interferon ɑ-2b va ginal effervescent capsules on eliminating HPV was observed.[Method]1.Females presented to our STD department,from June 2015 to June 2016,who were diagnosed by Condyloma acuminate and without any other clinica l symptoms were enrolled in the study.Samples of cervical exfoliated cells we re collected for the HPV(23HPV genotypes were detected,including HR-HPV: 16,18,31,33,35,39,45,51,52,53,56,58,59,66,68,73,82,83 and LR-HPV: 6,11,42,43,81 and Ct DNA detection via polymerase chain reaction(PCR).For the patients,whose warts were next to the edge of hymen,taking that samplin g may increase the chance of transmitting the HPV on surface of wart issues into vagina or cervix,their specimens were collected after the warts removed.We also recorded the cervical HPV results of females claiming a history of E GWs disgnosised by our hospital recently.2.The patients who showed cervical HPV-positive results were randomly di vided into treatment gruoup and control group.The treatment group were give n recombinant human interferon ɑ-2b vaginal effervescent capsules of 800,000 IU treatment.For pateints who presented only low-risk HPV infection were ap plied continuously for 12 days per month and the one with high-risk HPV inf ection taking continuous application of 20 days per Month.Meanwhile,the co ntrol group was no interfered.All of them received a second HPV test after taking Recombinant Human Interferon ɑ-2b vaginal effervescent capsules for thr ee months regularly and stopping it one month later and the twice results wer e recorded for comparison to observe the effect.[Results]1.123 females were enrolled in the study.The prevalence of cervical HPV,Ct and co-infection among females with external CA was 88.6%(109/123),22.7%(20/88),22.7%(20/88)respectively.75.6%(93/123)presented with cervi cal HR-HPV infection.2.65.0%(80/123)were multiple genotypes infection,13.0%(16/123)single LR-HPV genotype and 10.6%(13/123)single HR-HPV genotype,with HPV 16(31/109),52(16/109),18(14/109),51(13/109),58(13/109)and LR-HPV11(41/109),6(63/109)being the most common HPV genotypes.3.All the cases showed exact efficiency of Recombinant Human Interferon ɑ-2b vaginal effervescent capsules on eliminating cervical HPV with mild sedi effects.The total clearance rate was 65.2%,clearance rate of HR-HPV was 61.5%,clearance rate of LR-HPV was 70.4%.There was significant difference be tweent the treatmen group and control group.[Conclusion]Our results suggest that females with EGWs or a history of EGWS carry an obvious high prevalence of cervical HR-HPV and CT infection,especially t he co-infection and Recombinant Human Interferon ɑ-2b vaginal effervescent c apsules can effectively shorten the duration of HPV infection.An active screen ing for timely treatment of Chlamydia trachomatis infection and monitoring the cervical HPV regularly for this particular population are suggested in order to decrease CC incidence in a cost-effective manner. |
PDF Full Text Request